Early-onset Neonatal Infection Clinical Trial
— DIACORDOfficial title:
Diagnostic Performance Comparison Between Procalcitonin-based vs. ANAES-based Guidelines; Impact on Antibiotic Use in Newborns With Suspected Early-onset Neonatal Infection (EONI)
| NCT number | NCT02590198 |
| Other study ID # | RC15_0063 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | May 3, 2016 |
| Est. completion date | January 22, 2017 |
| Verified date | September 2019 |
| Source | Nantes University Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Neonatal bacterial infection remains a serious pathology in industrialized countries despite
the use of prophylaxis measures for group B streptococcus (GBS) (peri-partum antibiotic in
women with GBS colonization), which was implemented in the United States in 1996 and in
France in 2001 and has led to a dramatic decrease in the incidence of neonatal bacterial
infections. However, early onset neonatal infection (EONI), which is defined as an infection
occurring during the first 6 days after birth (as opposed to late onset neonatal infections
(LONI) occurring between days 7-89), is still one of the leading causes of neonatal morbidity
and mortality. Physicians consider EONI a significant diagnostic and therapeutic emergency
due to the potential for sudden onset and rapid evolution of sepsis in newborns with immature
immune systems. Currently, in France, detection of EONI is based on national consensus
guidelines published in 2002 (ANAES recommendations). There are broad indications to provide
empirical antibiotic treatment pending diagnostic confirmation through different
complementary exams. To ensure that every infected newborn is diagnosed, biological
assessments are often repeated and result in the use of invasive and painful procedures,
anemia and financial concerns. Moreover, in cases of abnormal biological results, many
newborns are subjected to intravenous (IV) antibiotic treatments requiring hospitalization
and separation from their mother. However recent studies have shown that antibiotics can have
a potentially deleterious effect on the neonatal digestive microbiota and result in the
appearance of antibiotic-resistant bacteria, with possible long-term consequences on the
health of the child.
Procalcitonin (PCT) is a calcitonin prohormone secreted from the parenchymal tissues. This
marker of inflammation has been shown to be a valuable diagnostic marker for bacterial
infection in adults and in children. It also seems to be a reliable marker for neonatal
bacterial infection, which would make it useful in the detection of EONI. Because
physiological levels of PCT vary during the first days of life, possibly due to postnatal
intestinal bacterial colonization, levels of this marker are difficult to interpret in the
early neonatal period. However, in a study of 2151 newborns with suspected EONI, Nicolas
Joram et al. found that PCT obtained from the umbilical blood cord, prior to newborn
intestinal colonization, bypasses this postnatal physiological peak of PCT and effectively
constitutes a discriminant marker to distinguish between infected and healthy infants using a
cutoff value of 0.6 ng/ml.
Subsequent to this pilot study, several studies on PCT in umbilical blood cord confirmed its
good diagnostic performance for EONI, particularly when included in a diagnostic algorithm.
This marker could contribute to a better estimation of EONI risk in order to limit the use of
unnecessary complementary exams and prescription of antibiotics and their associated short-
and long-term side effects in healthy newborns.
Therefore, in this study, the investigators propose to test the diagnostic value of a
PCT-based algorithm in newborns suspected of having EONI. The investigators hypothesize that
this algorithm is as efficient as those currently used (ANAES), but will limit coinciding
biological exams and exposure to antibiotics during the neonatal period.
| Status | Completed |
| Enrollment | 9201 |
| Est. completion date | January 22, 2017 |
| Est. primary completion date | January 22, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - All children born at > 36 weeks gestation in one of the 15 participating maternity or neonatology units and suspected having EONI according to the ANAES recommendations (clinical suspicion of chorioamnionitis, intrapartum maternal fever > 38°C, infected twin, spontaneous premature delivery at < 37 gestational weeks, prolonged rupture of membrane for > 12 hours, maternal group B Streptococcus colonization without full prophylactic antibiotic treatment, or signs of fetal asphyxia) will be included in the study. - Oral Consent (Non Opposition). Exclusion Criteria: - Newborns will be considered ineligible if: - Parental non opposition is not obtained, if the parents do not speak French, present severe dementia and/or cannot be reached on day 6. - Nosocomial neonatal infection, severe congenital malformation or obstetrically explained neonatal asphyxia are diagnosed. - Secondary parental opposition. |
| Country | Name | City | State |
|---|---|---|---|
| France | Angers University Hospital | Angers | |
| France | Bordeaux University Hospital | Bordeaux | |
| France | Brest University Hospital | Brest | |
| France | Créteil Intercommunal Center | Créteil | |
| France | Lorient Hospital | Lorient | |
| France | Private clinic - Polyclinique de l'Atlantique | Nantes | |
| France | La Pitié Salpétrière Hospital (AP-HP) | Paris | |
| France | Robert Debré Hospital (AP-HP) | Paris | |
| France | Saint Joseph Hospital | Paris | |
| France | Trousseau Hospital (AP-HP) | Paris | |
| France | Poissy-Saint germain Hospital | Poissy | |
| France | Poitiers University Hospital | Poitiers | |
| France | Rennes University Hospital | Rennes | |
| France | Tours University Hospital | Tours |
| Lead Sponsor | Collaborator |
|---|---|
| Nantes University Hospital | Centre Hospitalier de Bretagne Sud, Créteil Hospital, Nantes Polyclinic, Poitiers University Hospital, Rennes University Hospital, University Hospital, Angers, University Hospital, Bordeaux, University Hospital, Brest, University Hospital, Paris, University Hospital, Tours |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Primary outcome is a composite outcome including: death from any cause, intensive care unit admission for any reason, disease-specific complications, diagnosis of EONI after maternity discharge, need for antibiotics with hospital readmission | The primary noninferiority endpoint is a composite of overall adverse outcomes induced by EONI occuring within 6 days following birth. It includes death, Neonatal Intensive care Unit (NICU) admission, or hospital readmission. The investigators chose this primary endpoint because the French definition of EONI diagnostic is subjective, specifically in case of possible EONI in case of gastric fluid positivity, and is finally rarely objectivated. Moreover, the new PCT-based algorithm do not require any gastric fluid analysis and modify the usual French definition of possible EONI, impossible to use in this context. Focusing on serious adverse event outcomes seems a very pragmatic and efficient methodologic strategy. | 6 days after birth | |
| Secondary | death | components of the primary outcome (death/NICU/rehospitalisation + antibiotics) will be considered independently, as is advised for a composite outcome. | Day 6 and Day 90 | |
| Secondary | NICU admission | components of the primary outcome (death/NICU/rehospitalisation + antibiotics) will be considered independently, as is advised for a composite outcome. | Day 6 and Day 90 | |
| Secondary | rehospitalisation in connection with antibiotic treatment | components of the primary outcome (death/NICU/rehospitalisation + antibiotics) will be considered independently, as is advised for a composite outcome. | Day 6 and Day 90 | |
| Secondary | Inter-period frequency comparison of secondary adverse effect (SAE) and adverse effect (AE) related to antibiotics. | Day 6 and Day 90 | ||
| Secondary | Number of blood samples induced by the 2 algorithms | EONI diagnostic exams frequency for EONI induced by the 2 algorithms (number of blood samples) | Day 6 and Day 90 | |
| Secondary | Number of newborns investigated by the 2 algorithms | EONI diagnostic exams frequency for EONI induced by the 2 algorithms ( number of newborns investigated). | Day 6 and Day 90 | |
| Secondary | Inter-period cumulated hospital stay length (including maternity stay) | Day 90 | ||
| Secondary | clinical and biological description of EONI and LONI | Description of EONI and LONI bacteriological epidemiology (No recent data in France and Europe): frequency, typology... | 12 months |